Baker Bros. Advisors LP Verastem, Inc. Transaction History

Baker Bros. Advisors LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.39 - $0.71 $572,305 - $1.04 Million	-1,467,451 Reduced 5.44%	25,521,447 $10.7 Million
Q1 2022 May 16, 2022	BUY	$1.06 - $2.1 $5.83 Million - $11.5 Million	5,497,268 Added 25.58%	26,988,898 $38.1 Million
Q2 2021 Aug 16, 2021	BUY	$2.57 - $4.85 $11.5 Million - $21.7 Million	4,472,336 Added 26.28%	21,491,630 $87.5 Million
Q1 2021 May 17, 2021	BUY	$1.9 - $2.82 $13.1 Million - $19.4 Million	6,875,255 Added 67.78%	17,019,294 $42 Million
Q4 2020 Feb 16, 2021	BUY	$1.15 - $2.4 $11.7 Million - $24.3 Million	10,144,039 New	10,144,039 $21.6 Million

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.17B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.